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4-APAbstract Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system
(CNS), causes irreversible disability in young adults but the cause and cure were unknown and it
involves two arms: and causes demyelination and neurodegeneration. In the case of MS the massive
activation of the immune system against putative CNS antigen leads to the loss of oligodendrocyte/
myelin complex which slows down the impulse conduction in denuded axons. In demyelination dis-
eases (e.g. MS) denuded axons frequently occur without axonal loss that is so characteristic of radi-
ation injury. Since, the treatment strategies for MS have increased rapidly but still proper
knowledge regarding the nature of MS cleared the way for several more speciﬁc, more effective,
and more comfortable therapies. Here, because of the stimulating recent developments about oral
treatment for MS, the current state of approved and future therapy options were summarized here.
In particular, we highlight oral treatment options in MS and dalfampridine (4-aminopyridine) is an
oral potassium channel blocker, which was recently approved by FDA (Food and Drug Adminis-
tration) for symptomatic treatment of MS, it acts at the central and peripheral nervous systems,
enhances conduction in demyelinated axons, and improves the walking ability of MS patients.
Moreover number of clinical trials has evaluated the safety and efﬁcacy of fampridine in MS
S1444 M. Malhotra et al.patients and it represents a major advance in symptomatic therapy for MS. The objective of this
manuscript is to provide an overview of the Chemistry, mechanism of action, pharmacodynamics,
pharmacokinetics, preclinical and clinical studies, dosage and administration, side effects, contrain-
dication, proper usage, and drug interaction of dalfampridine used in the treatment of MS patients.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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Dalfampridine was approved by United State Food and Drug
Administration (FDA) on January 22, 2010 and it is launched
by Acorda therapeutics under the trade name AMPYRA
which is used to improve walking in people suffering from mul-
tiple sclerosis (MS). The FDA granted dalfampridine orphan
drug status, providing them 7 years of market exclusivity for
the drug (Confavreux et al., 2000). The drug, a potassium
channel blocker, was shown in clinical trials to improve walk-
ing speeds vs placebo and it acts by enhancing conduction in
damaged nerves. Trouble with walking is one of the most
debilitating problems of MS patients. The drug was previously
known as fampridine sustained release with the proposed
brand name Ampyra, but is now called dalfampridine (Rudick
et al., 2010). Multiple sclerosis is a chronic disease that attacks
the immune system and results in the degradation of nervous
system functioning. MS is a disorder of the body’s immune
system that affects the central nervous system (CNS). Nor-
mally, nerve ﬁbers carry electrical impulses through the spinal
cord, providing communication between the brain, arms and
legs. In people with MS, the fatty sheath that surrounds and
insulates the nerve ﬁbers called myelin deteriorates, causing
nerve impulses to be slowed or stopped (Compston and Coles,2008; Rosati, 2001). So, the person suffering from multiple
sclerosis may experience periods of muscle weakness, loss of
vision, loss of coordination, paralysis, spasticity, physical
fatigue and decreased ability to think or remember. So, contin-
uing in the advancement of clinical research and expansion of
therapeutic options for people with MS, including treatments
for the most debilitating symptoms and challenges associated
with this disease, is critical to helping people with MS (Clanet,
2008; Compston and Coles, 2002; Ascherio and Munger, 2007;
Lublin and Reingold, 1996). Fampridine has been used clini-
cally in Lambert–Eaton myasthenic syndrome and multiple
sclerosis. It acts by blocking potassium channels, prolonging
action potentials and thereby increasing neurotransmitter re-
lease at the neuromuscular junction. The drug has been shown
to reverse tetrodotoxin toxicity in animal experiments (Wein-
shenker, 1994; Pittock and Rodriguez, 2008). Fampridine has
been shown to improve visual function and relieve fatigue in
patients with multiple sclerosis (Judge and Bever, 2006). 4-
AP is most effective in patients with the chronic progressive
form of MS, in patients who are temperature sensitive, and
in patients who have been suffering from MS for longer than
3 years. These periods of illness may become exacerbations
and go into remissions. Fampridine-SR is an experimental
drug that has been reported to possibly improve muscle
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swijk and Balesar, 2003). 4-Aminopyridine has a restricted
use as an extremely effective bird poison sold under the brand
name Avitrol, and may be dangerous to mammals and other
animals. The most common target birds are pigeons, house
sparrows, and starlings, if dosages are exceeded, compound
forms of the active agent of sustained-release fampridine have
been used in clinical practice for many years and are shown to
improve walking ability in patients with multiple sclerosis.
Clinical trials have now been completed that demonstrate
effectiveness of the drug with statistical signiﬁcance and a clin-
ically meaningful end point. Approval of dalfampridine will
enable patients to obtain a consistent exact dosage in a guaran-
teed time-released formula, and avoid the risk of getting an
uncertain preparation from a compounding pharmacy with
possible adverse effects (Vandiemen et al., 1993).
2. Chemistry
4-Aminopyridine (dalfampridine) is an organic compound with
the chemical formula H2NC5H4N. It is prepared by the decarb-
onylation of pyridine-4-carboxamide using sodium hypochlo-
rite via Hoffman rearrangement. The pyridine carboxamide is
generated from the corresponding nitrile, which in turn is ob-
tained from the ammoxidation of 4-methylpyridine. The mole-
cule is one of the three isomeric amines of pyridine. It is used
primarily as a research tool, in characterizing subtypes of potas-
sium channel, and has also been used to manage some of the
symptoms of multiple sclerosis. The largest scale industrial
application of 4-aminopyridine acts as a precursor to the drug
pinacidil, which affects potassium ion channels. In the labora-
tory, 4-AP is a useful pharmacological tool in studying various
potassium conductances in physiology and biophysics. It is a
relatively selective blocker of members of Kv1 (family of volt-
age-activated K+ channels.). At concentration of 1 mM it
selectively and reversibly inhibits shaker channels without
signiﬁcant effect on other sodium, calcium, and potassium con-
ductances (Korenke et al., 2008).
3. Mechanism of action
Dalfampridine blocks tiny pores, or potassium channels, on
the surface of nerve ﬁbers, which may improve the conduction
of nerve signals along nerve ﬁbers whose insulating myelin
coating has been damaged by MS, available in 10 mg tablet
strength. It is a broad-spectrum potassium channel blocker
that does not have a clinically important effect on duration
of the QRS interval and it does not prolong the QTc interval,
according to the FDA-approved for Ampyra. In animal stud-
ies, dalfampridine-mediated inhibition of potassium channels
increased the conductivity of demyelinated nerve ﬁbers. Elec-
trophysiologic studies of demyelinated axons show that aug-
mented potassium currents increase extracellular potassium
ion concentration which decreases action potential duration
and amplitude which may cause conduction failure. Potassium
channel blockade reverses this effect. However, a recent study
has shown that 4-AP is a potent calcium channel activator and
can improve synaptic and neuromuscular function by directly
acting on the calcium channel beta subunit (b1). MS patients
treated with 4-AP exhibited a response rate of 29.5% to
80%. A long-term study (32 months) indicated that 80–90%of patients who initially responded to 4-AP exhibited long-
term beneﬁts. Although improving symptoms, 4-AP does not
inhibit the progression of MS. Spinal cord injury patients have
also seen improvement with 4-AP therapy. These improve-
ments include sensory, motor and pulmonary function, with
a decrease in spasticity and pain (Zi-Zhen et al., 2009; Shrager,
1989; Chiu and Ritchie, 1980).
4. Pharmacodynamics
In Idiopathic unknown Pharmacodynamics, dalfampridine is a
broad-spectrum voltage-gated potassium channel blocker, can
increase action potential duration and amplitude, leading to
improved demyelinated nerve ﬁbers (loss of the myelin sheath
insulating the nerves, and is the hallmark of some neurodegen-
erative autoimmune diseases, including multiple sclerosis, acute
disseminated encephalomyelitis, transverse myelitis, chronic
inﬂammatory demyelinating polyneuropathy, Guillain–Barre´
syndrome, central pontine myelinosis, inherited demyelinating
diseases such as Leukodystrophy, and Charcot Marie Tooth)
conduction and increase of neurotransmitter release at the syn-
aptic ending. The metabolites have been shown to have no
pharmacologic activity on potassium channels. Blocking volt-
age-gated potassium channels facilitates direct blocking of the
synaptic and neuromuscular transmits ions conventionally
and it was also suggested that fampridine can directly target
presynaptic high voltage-activated calcium channels to potenti-
ate neurotransmitter release independent of potassium chan-
nels. AMPYRA does not prolong the QTc interval and does
not have a clinically important effect on QRS duration (Robert
and Jeffrey, 2011; Peter et al., 2011).
5. Pharmacokinetics
Dalfampridine, a sustained-release oral preparation of fampri-
dine, is rapidly absorbed, but relative bioavailability is 96%
when compared to an aqueous oral solution. It gives a slower
rise to a lower peak concentration Cmax (term used in pharma-
cokinetics refers to the maximum concentration that a drug
achieves in the tested area after the drug has been administrated
and prior to the administration of a second dose) i.e. 3–4 h post
administration, with no effect on the extent of absorption AUC
(area under curve). When dalfampridine is taken with food,
there is a slight increase in Cmax (12–17%) and a slight decrease
in AUC (4–7%). Dalfampridine was nearly completely (95.5%)
and rapidly eliminated within 24 h as unchanged drug via
urinary excretion and 0.5% recovered in feces suggesting that
it is unlikely to undergo substantial metabolic transformation
with mean terminal disk position, half-life is 6.4 h and plasma
half life of about 7.6 h in healthy individuals. Dalfampridine
is largely unbound to plasma proteins (97–99%). The apparent
volume of distribution is 2.6 L/kg. Two metabolites were iden-
tiﬁed: 3-Hydroxy-4-aminopyridine (4.3%) and 3-hydroxy-4-
aminopyridine sulfate (2.6%). In vitro studies with human liver
microsomes indicate that CYP2E1 was the major enzyme
responsible for the 3-hydroxylation of dalfampridine. The
identity of the CYP enzymes suspected of playing a minor role
in the 3-hydroxylation of dalfampridine could not be estab-
lished unequivocally (Vollmert and Henney, 2009; Judge
et al., 2006; Bever and Judge, 2009; Oh et al., 2009; Chang
et al., 1997; Uges et al., 1982).
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6.1. Carcinogenesis
Two year dietary carcinogenicity studies of dalfampridine were
conducted in mice and rats. In mice, the doses tested (approx-
imately 2, 12.5, and 80 mg/kg/day) were associated with plasma
exposures (AUC) up to 18 times the plasma AUC in humans at
the maximum recommended human dose (MRHD) of 20 mg/
day. There was no evidence of drug-related carcinogenicity.
In rats, the doses tested (approximately 2, 6, and 18 mg/kg/
day) were approximately one, three, and nine times the MRHD
on a body surface area (mg/m2) basis. There was a signiﬁcant
increase in uterine polyps at the highest dose tested.
6.2. Mutagenesis
Dalfampridine was negative in in vitro (bacterial reverse muta-
tion, mouse lymphoma, and chromosomal aberration) and
in vivo (mouse bone marrow, rat erythrocyte micronucleus)
genetic toxicology assays.
6.3. Impairment of fertility
Oral administration of dalfampridine (doses of 1, 3, and 9 mg/
kg/day) to male female rats prior to and throughout mating,
and continuing in females up to day 13 of gestation or 21 of
lactation resulted in no adverse effects on fertility. Reduced
offspring viability and body weight were at 9 mg/kg/day. The
mid dose (a no-effect dose) was similar to the MRHD on
mg/m2 basis (Stephen Krieger, 2011).
7. Clinical study
It was estimated that about 400,000 Americans were suffering
from multiple sclerosis and 64–85% of patients will have difﬁ-
culty in walking within 15 years of diagnosis. Dalfampridine is
the ﬁrst and only FDA-approved oral drug addressing walking
impairment in patients with multiple sclerosis (Goodman et al.,
2009; Johnson and Morgan, 2006).
7.1. Phase ﬁrst
Single AMPYRA tablet 10 mg dose administered to healthy
volunteers in a fasted state gave peak concentrations ranging
from 17.3 ng/mL to 21.6 ng/mL occurring 3–4 h post-adminis-
tration Tmax (The amount of time that a drug is present at the
maximum concentration in serum.). In comparison, Cmax with
the same 10 mg dose of dalfampridine in an oral solution was
42.7 ng/mL and occurred approximately 1.3 h after dosing.
Exposure increased proportionally with dose. Common side
effects include dizziness, nervousness and nausea, and inci-
dence of adverse effects was shown to be less than 5% in all
studies (Smith et al., 2010).
7.2. Phase second
In a phase II trial, percentage improvements in walking speed
on the timed 25-foot walk test (primary endpoint) were not
signiﬁcant versus baseline or placebo during treatment withdalfampridine ER 10, 15 or 20 mg twice daily. But according
to a post hoc, response rates were signiﬁcantly higher with dal-
fampridine ER than placebo, with a consistent mean improve-
ment in walking speed of 25–29% seen in the pooled results
from dalfampridine ER responders during the double-blind
treatment period (Goodman et al., 2008). In placebo-con-
trolled clinical trials of dalfampridine lasting up to 14 weeks
duration, 4% of patients treated with dalfampridine had treat-
ment emergent adverse events leading to discontinuations
compared with 2% of placebo-treated patients. The treatment
emergent adverse events led to discontinuation of at least two
patients treated with dalfampridine and those that led to dis-
continuation more frequently compared with the placebo were
headache (dalfampridine 0.5% vs placebo 0%), balance disorder
(dalfampridine 0.5% vs placebo 0%), dizziness (dalfampridine
0.5% vs placebo 0%), and confusional state (dalfampridine
0.3% vs placebo 0%) (Goodman et al., 2002; Schwid et al., 1997).
7.3. Phase third
Allocation: randomized, Control: Placebo control, Endpoint
classiﬁcation: Safety/efﬁcacy study, Intervention model: paral-
lel assignment, Masking: double blind (subject, caregiver,
investigator, and outcomes assessor), Primary purpose: treat-
ment. In two phase III clinical trials, a signiﬁcantly greater
proportion of people on therapy had a consistent improvement
in walking speed compared to those in the placebo group. In
the ﬁrst trial, involving 301 people with any type of MS, walk-
ing speed increased by 25% compared with the placebo
(Goodman et al., 2009). Results from the second phase III
study, involving 240 people with MS, conﬁrmed the beneﬁts
seen in the ﬁrst trial. Among those taking dalfampridine who
improved in walking speed, there was also a statistically signif-
icant improvement in leg strength. AMPYRA has been evalu-
ated in a total of 1952 subjects, including 917 MS patients. A
total of 741 patients have been treated with AMPYRA for
over 6 months, 501 for over 1 year and 352 for over 2 years
(Goodman et al., 2007). The experience in open-label clinical
trials is consistent with the safety proﬁle observed in the pla-
cebo-controlled clinical trials. As in controlled clinical trials,
a dose-dependent increase in the incidence of seizures has been
observed in open-label clinical trials with AMPYRA in pa-
tients with MS as follows: AMPYRA 10 mg twice daily 0.41
per 100 person-years; dalfampridine 15 mg twice daily 1.7
per 100 person-years. Trial 1 was a randomized, placebo-con-
trolled, parallel group, 21-week study (1 week post screening,
2-week, single-blind placebo run-in, 14-week double-blind
treatment, and 4-week no treatment follow-up) in 301 patients
with multiple sclerosis at 33 centers in the U.S. and Canada:
229 patients assigned to AMPYRA 10 mg twice daily and 72
patients assigned to placebo. A total of 283 patients (212
AMPYRA and 71 placebo) completed all study visits. Patient
inclusion criteria included the ability to walk 25 feet in 8–45 s.
Patient exclusion criteria included a history of seizures or evi-
dence of epileptic form activity on a screening EEG, and onset
of an MS exacerbation within 60 days (Goodman et al., 2010).
7.4. Trial one
This randomized, placebo-controlled, parallel group, 21-week
study enrolled 301 patients with multiple sclerosis at 33 centers
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10 mg twice daily or placebo. A total of 283 subjects completed
the study. The primary measure of efﬁcacy was walking speed
(in feet per second) as measured by the Timed 25-foot Walk
(T25W), using a responder analysis. A signiﬁcantly greater
proportion of patients taking Ampyra were responders com-
pared to patients taking placebo: 34.8% vs 8.3%, respectively.
The increased response rate was observed across all four major
types of MS disease course (Goodman et al., 2007, 2009, 2010).
During the double-blind treatment period, a signiﬁcantly
greater proportion of patients taking Ampyra 10 mg twice dai-
ly had increases in walking speed of at least 10%, 20%, or 30%
from baseline, compared to placebo.
7.5. Trial two
This randomized, placebo-controlled, parallel group, 14-week
study enrolled 239 patients with multiple sclerosis at 39 centers
in the U.S. and Canada. The subjects were assigned to 10 mg
twice daily and or placebo. A total of 227 patients completed
the study. The primary endpoint was walking speed (in feet
per second) as was measured by the Timed 25-foot Walk
(T25W), using a responder analysis. A signiﬁcantly greater
proportion of patients taking Ampyra were responders com-
pared to patients taking placebo: 42.9% vs 9.3%, respectively.
The increased response rate was observed across all four major
types of MS disease course. During the double-blind treatment
period, a signiﬁcantly greater proportion of patients taking
Ampyra 10 mg twice daily had increases in walking speed of
at least 10%, 20%, or 30% from baseline, compared to the
placebo. In Trial 1 and Trial 2, consistent improvements in
walking speed were shown to be associated with improvements
on a patient self-assessment of ambulatory disability, the 12-
item Multiple Sclerosis Walking Scale (MSWS-12), for both
drug and placebo treated patients. However, a drug-placebo
difference was not established for that outcome measure.
The majority of patients in these trials (63%) were using
immunomodulatory drugs (interferons, glatiramer acetate, or
natalizumab), but the magnitude of improvement in walking
ability was independent of concomitant treatment with these
drugs. No differences in effectiveness based on degree of
impairment, age, gender, or body mass index were detected.
There were too few non-Caucasians in the patient population
to evaluate the effect of race (Goodman et al., 2007, 2009,
2010).
8. Dosage and administration
The maximum recommended dose of AMPYRA is one 10 mg
tablet twice daily, taken with or without food. Doses should be
taken approximately 12 h apart. Patients should not taken
double or extra doses if a dose is missed. No additional beneﬁt
was demonstrated at doses greater than 10 mg twice daily and
adverse reactions and discontinuations were more frequent at
higher doses. Tablets should only be taken whole; do not di-
vide, crush, chew, or dissolved. AMPYRA is contraindicated
in patients with moderate or severe renal impairment. The sei-
zures in patients with mild renal impairment (CrCl 51–80 mL/
min) is unknown, but AMPYRA is contraindicated in patients
with moderate or severe renal impairment. The risk of seizures
in patients with mild renal impairment (CrCl 51–80 mL/min) isunknown, but AMPYRA plasma exposure in these patients
may approach that seen at a dose of 15 mg twice daily dose
that may be associated with an increased risk of seizures; esti-
mated CrCl should be known before initiating treatment with
AMPYRA (Lawrence and Andrew, 2011).
8.1. Side effects
Urinary tract infection was the most common adverse event
associated with dalfampridine during clinical trials. Given at
doses greater than the recommended 10 mg twice a day, dal-
fampridine can cause seizures, balance disorder, swelling in
the nose or throat, constipation, diarrhea, indigestion, throat
pain, and burning, tingling, itching of skin, insomnia, dizziness,
headache, nausea, asthenia, back pain, balance disorder, multi-
ple sclerosis relapse, paresthesia, nasopharyngitis, constipation,
dyspepsia, pharyngolaryngeal pain, problems with balance, MS
relapse, burning, tingling or itching of the skin, irritation of the
nose and throat, constipation, indigestion and throat pain
(Pickett and Enns, 1996; Johnson and Morgan, 2006).9. Contraindication
Dalfampridine is contraindicated in patients with moderate to
severe kidney disease because the blood levels with the drug
approach those associated with the occurrence of seizures. Be-
cause of concern for this adverse event, dalfampridine is con-
traindicated in patients with a prior history of seizure and
should be discontinued in patients in which seizure occurs.
Dalfampridine should not be consumed by pregnant women,
children less then 18 years of age and it should not be taken
with other aminopyridine medications. Dalfampridine demon-
strated efﬁcacy in all four major types of MS, including relaps-
ing-remitting, secondary progressive, progressive relapsing,
and primary progressive, and can be used alone or in combina-
tion with immunomodulatory drugs (Smith et al., 2010; Peter
et al., 2011).
9.1. Proper usage
Dalfampridine should be kept out of the reach of children and
should not take more than two tablets in a 24-h period. The
medication can be taken with or without food but it should
never chewed and crushed before swallowing because it may
cause the medication to release too quickly, which may in-
crease the risk of having a seizure. Suppose if a dose of dalfam-
pridine is missed then never stop the therapy but continue with
the next dose at your regular scheduled time (Schapiro et al.,
2010).
9.2. Speciﬁc populations
The safety and effectiveness of AMPYRA in patients younger
than 18 years of age have not been established. It is known to
be substantially excreted by the kidney and the risk of adverse
reactions including seizures increases with the exposure to dal-
fampridine. Because elderly patients are more likely to have
decreased renal function, it is particularly important to know
the estimated creatinine clearance (CrCl) in these patients. A
population pharmacokinetic analysis suggested that female
S1448 M. Malhotra et al.patients would be expected to have higher maximum dalfam-
pridine plasma concentration (Cmax) than male patients. The
pharmacokinetics of dalfampridine was studied in nine male
and 11 female subjects with varying degrees of renal function.
Total blood clearance of dalfampridine was reduced by about
45% in patients with mild renal impairment (CrCl 51–80
mL/min), by about 50% in patients with moderate renal
impairment (CrCl 30–50 mL/min), and by about 75% in pa-
tients with severe renal impairment (CrCl < 30 mL/min).
The terminal half-life of dalfampridine is about 3.3 times long-
er in patients with severe renal impairment but is not pro-
longed in patients with mild or moderate renal impairment.
Since dalfampridine is primarily excreted unchanged in urine,
hepatic impairment is not expected to signiﬁcantly affect
dalfampridine pharmacokinetics or recommended dosing.
AMPYRA should be used during pregnancy only if the poten-
tial beneﬁt justiﬁes the potential risk to the fetus. No evidence
of developmental toxicity was found in either species at the
highest doses tested, which were maternally toxic. Oral admin-
istration of dalfampridine (at doses of 1, 3, and 9/6 mg/kg/day;
high dose reduced during the second week of dosing) to rats
throughout the pregnancy and lactation periods resulted in de-
creased offspring survival and growth (Goodman et al., 2007,
2009, 2010). The no-effect dose for pre- and postnatal develop-
mental toxicity in rats (1 mg/kg) is approximately 0.5 times the
MRHD on mg/m2 basis.
9.3. Drug interactions
Dalfampridine kinetics was not affected by co-administration
of subcutaneous injections of eight million unit’s interferon
beta-1b. No pharmacokinetic drug–drug interaction was ob-
served with co-administration of dalfampridine 15 mg and
baclofen 10 mg. In vitro data with human liver microsomes
showed that dalfampridine was not a direct or time-dependent
inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, or CYP3A4/5. Dalfampridine is not
likely to affect the pharmacokinetics of drugs that are sub-
strates of these enzymes. Other in vitro studies with cultured
human hepatocytes with dalfampridine had little or no effect
on CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2E1 or
CYP3A4/5 enzyme activities. Consequently, the potential for
dalfampridine to induce human hepatocytes at therapeutic
concentrations is remote. In vitro, dalfampridine is not a
substrate or an inhibitor for the p-glycoprotein transporter
(Goodman et al., 2010; Goodman et al., 2009; Goodman
et al., 2007). The pharmacokinetics of AMPYRA is unlikely
to be affected by drugs that inhibit the p-glycoprotein trans-
porter, and dalfampridine is not likely to affect the pharmaco-
kinetic of drugs that are substrates of the p-glycoprotein
transporter.10. FDA approval and market authorization
On January 30, 2009 Acorda Therapeutics, announced the
submission of a new drug application to the U.S. (FDA) for
Fampridine-SR. Fampridine-SR was accepted by the FDA
on May 5, 2009. The FDA set a prescription drug user fee
act (PDUFA) on October 22, 2009; the PDUFA date is the
target date for the FDA to complete its review. On May 6,
2009 acorda therapeutics, announced that the U.S. (FDA)has accepted the Fampridine-SR New Drug Application
(NDA) for ﬁling, assigning priority review and on Aug 25,
2009 Acorda Therapeutics, announced that the U.S. (FDA)
has conﬁrmed that its Peripheral and Central Nervous System
Drugs Advisory Committee will review the Company’s New
Drug Application (NDA) for Fampridine-SR on October 14,
2009 and Acorda submitted additional information on its pro-
posed Risk Evaluation and Mitigation Strategy (REMS) pro-
gram. The Company also announced that it has received
preliminary approval for the proposed trade name Amaya
from the FDA. On 12 January 2010, Biogen Idec announced
that the submission of a Marketing Authorization Application
(MAA) to the European Medicines Agency for prolonged re-
lease fampridine tablets helpful in the walking ability of adult
patients suffering from multiple sclerosis. The US FDA ac-
cepted this submission as a solicited major amendment to the
Fampridine-SR NDA. FDA approved dalfampridine in pa-
tients with multiple sclerosis on January 22, 2010. Biogen Idec
will commercialize fampridine as a prolonged release tablet in
markets outside the U.S.11. Conclusion
In the case of multiple sclerosis there is conduction abnormal-
ity, including conduction delay or block due to the loss of the
oligodendrocyte myelin complex which in turn results in the
reorganization of axolemmal ion channels. So, the agents
which block potassium channels have been investigated in
the context of clinical trials with positive impact on impulse
conduction in experimentally-induced demyelination in
MS patients. Dalfampridine is an extended release form of
fampridine (4-aminopyridine), which has been recently been
approved by the US FDA for symptomatic treatment of MS
patients. While this new oral blocker of voltage-gated potas-
sium channels does not have any impact on the underlying
pathology of MS, it has been demonstrated to improve fatigue
and walking ability in these patients.
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